HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
ID: 360385Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/360385
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity for the HEAL Initiative: Pain Management Effectiveness Research Network, specifically for Clinical Trial Planning and Implementation through a Cooperative Agreement (UG3/UH3). This initiative aims to conduct large-scale, multisite clinical trials that will evaluate the efficacy of interventions designed to reduce opioid use and improve pain management across various conditions, thereby enhancing functional outcomes for patients suffering from acute to chronic pain. The program is critical in expanding evidence-based therapeutic options for pain relief, benefiting patients and their families. Interested applicants, including various eligible entities such as tribal governments and community organizations, are encouraged to prepare for this opportunity, with applications expected to be solicited starting October 15, 2025, and closing on January 5, 2026. For further inquiries, potential applicants can contact Dr. Yolanda F. Vallejo at 301-451-1751 or via email at Yolanda.Vallejo@nih.gov.

    Point(s) of Contact
    Yolanda F. Vallejo, PhD
    (301) 451-1751
    Yolanda.Vallejo.nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative to support the development of non-addictive analgesic therapeutics, specifically small molecules and biologics, aimed at treating pain. The initiative seeks to accelerate the optimization and transition of promising therapeutic candidates to Phase I clinical trials, requiring applicants to demonstrate a compelling biological rationale and suitable assays for their projects. This funding is crucial for addressing the needs of over 25 million Americans suffering from chronic pain while providing alternatives to opioids. Approximately $11 million is anticipated for distribution across four awards in FY 2024, with applications due by January 24, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Network (ERN) (Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "Limited Competition: HEAL Initiative Resource Centers for the Pain Management Effectiveness Network (ERN) (Clinical Trial Not Allowed)." This initiative aims to renew the HEAL Pain Management Effectiveness Research Network Resource Centers, which are essential for planning, implementing, and completing large-scale multisite clinical trials focused on effective pain management strategies across various diseases and conditions. The Resource Centers will provide operational expertise, clinical coordination, data management, and recruitment support to enhance pain management research. Interested applicants must be recipients of RFA-TR-22-012, with applications peer-reviewed for merit. The estimated award date is August 2, 2027, and the project is expected to commence on September 2, 2027. For further inquiries, contact Yolanda F. Vallejo, PhD, at yolanda.vallejo@nih.gov or call 301-451-1751.
    Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: NIH-DOD-VA Pain Management Collaboratory � Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the HEAL Initiative, specifically targeting the NIH-DOD-VA Pain Management Collaboratory to support pragmatic and implementation science demonstration projects. This initiative aims to conduct large-scale clinical trials focusing on nonopioid pain management strategies and addressing opioid misuse among U.S. Veterans, military personnel, and their families. The funding opportunity, which will be structured as a cooperative agreement, is expected to provide approximately $850,000 for one award, with the NOFO anticipated to be published in Fall 2024 and applications due by November 2024. Interested applicants should prepare to develop collaborative projects that align with the goals of the Pain Management Collaboratory, with an estimated award date set for July 1, 2025.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the HEAL Initiative aimed at supporting research for non-opioid analgesics via the R61/R33 Exploratory/Developmental Phased Award. This initiative encourages applications that focus on the early translational steps in developing novel pain treatment strategies, including the development and validation of assays and the identification of potential therapeutic agents, while explicitly prohibiting clinical trials. The funding amount is up to $350,000 per year, with a total project period not exceeding three years, and applications are due by January 15, 2027. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the HEAL Initiative's funding opportunity titled "Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)." This initiative aims to support pilot projects that identify new druggable targets for pain by generating preliminary data on understudied proteins associated with pain management. The funding opportunity is particularly significant as it seeks to advance research in pain management and drug discovery, contributing to the broader goal of addressing the opioid addiction crisis. Eligible applicants can receive up to $100,000 for projects lasting one year, with applications due by July 16, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-197.html.
    Forecast for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative for the development of non-addictive analgesic therapeutics, specifically targeting small molecules and biologics to treat pain. This cooperative agreement aims to accelerate the discovery and optimization of promising therapeutic candidates, facilitating their readiness for Phase II clinical studies, while excluding basic research and clinical studies beyond Phase I. The program encourages collaborations among researchers with expertise in pain therapeutics development, with applications expected to be submitted by early 2026, and an estimated award date set for September 2026. For further inquiries, interested parties can contact Dr. Mohamed Hachicha at 301-496-1779 or via email at mohamed.hachicha@nih.gov.
    HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "HEAL Initiative: Integrative Management of Chronic Pain and Opioid Use Disorder (OUD) for Whole Recovery: Health Systems." This initiative aims to develop strategies to enhance the sustainable and effective delivery of integrated care for individuals suffering from both chronic pain and OUD, addressing barriers at the health systems level. The importance of this opportunity lies in its focus on improving collaborative care models and implementation strategies to better manage these co-occurring conditions, which affect a significant portion of the population. Interested applicants, particularly small businesses with expertise in chronic pain management and OUD, are encouraged to prepare for the application process, with the estimated synopsis post date set for January 12, 2026, and the estimated award date anticipated for April 1, 2027. For further inquiries, potential applicants can contact Shelley Su, Ph.D., at IMPOWR@nih.gov or by phone at 301-402-3869.
    HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative aimed at identifying new druggable targets for pain related to understudied proteins. This initiative invites pilot projects that focus on generating preliminary data on specific eligible proteins, particularly those with a PubMed score of less than 10, which are considered understudied and may lead to innovative pain treatments. The funding opportunity, which provides up to $100,000 for a one-year project, emphasizes the importance of diversity in applicant teams and requires coordination among grant recipients. Interested applicants should note that the application submission period begins on January 16, 2025, and clinical trials are not permitted under this grant. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-154.html.
    HEAL NOFO for the HEAL INTERACT Data Center
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a Notice of Funding Opportunity (NOFO) for the HEAL INTERACT Data Center, aimed at addressing musculoskeletal and peripheral pain through integrated research initiatives. This cooperative agreement seeks to fill knowledge gaps and identify novel research directions in the field, encouraging collaborative investigations among experts in pain mechanisms. While applications are not currently being solicited, potential applicants are urged to prepare meaningful collaborations and responsive projects, with an estimated synopsis post date of September 25, 2025, and a projected award date of August 3, 2026. For further inquiries, interested parties can contact Dr. Rebecca Lenzi at rebecca.lenzi@nih.gov or by phone at 301-408-7447.